The AstraZeneca US Phase III trial of AZD 1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and… read more.
Pfizer Inc. and BioNTech SE announced that, in a Phase III trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection,… read more.
Celltrion Group announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for the company’s anti-COVID-19 monoclonal antibody… read more.
Positive high-level results from the primary analysis of the Phase III trial of AZD 1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis… read more.
The Israel Ministry of Health (MoH), Pfizer Inc. and BioNTech SE announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the… read more.
The Medicines Health Regulatory Authority (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks.
Johnson & Johnson welcomes the interim recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) supporting the use of Johnson… read more.
Johnson & Johnson announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine JNJ 78436735, developed by the Janssen Pharmaceutical… read more.
Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19) and a related shot by the Serum Institute of India for use in Canada.
Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety… read more.
Ocugen announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase III study of Covaxin, a whole virion inactivated COVID-19… read more.
Pfizer Inc.and BioNTech SE announced they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
